Differences in the Prognosis according to the Periods of Diagnosis in Ulcerative Colitis.
- Author:
Hyun Beom CHAE
1
;
Yoon Suk JUNG
;
Dong Il PARK
;
Chang Kyun LEE
;
Kyu Chan HUH
;
Jeong Eun SHIN
;
Jae Hak KIM
;
You Sun KIM
;
Yunho JUNG
;
Sung Ae JUNG
;
Hyun Ju SONG
;
Hyun Joo JANG
;
Sung Noh HONG
;
Young Ho KIM
Author Information
- Publication Type:English Abstract ; Original Article
- Keywords: Ulcerative colitis; Infliximab; Steroid, refractory; Surgery
- MeSH: Adult; Anti-Inflammatory Agents, Non-Steroidal/therapeutic use; Colitis, Ulcerative/*diagnosis/drug therapy/pathology; Female; Follow-Up Studies; Hospitalization; Humans; Infliximab/therapeutic use; Logistic Models; Male; Mesalamine/therapeutic use; Middle Aged; Odds Ratio; Prognosis; Retrospective Studies; Time Factors
- From:The Korean Journal of Gastroenterology 2014;64(2):93-97
- CountryRepublic of Korea
- Language:Korean
- Abstract: BACKGROUND/AIMS: Infliximab was approved for the treatment of ulcerative colitis (UC) in 2006 and has recently been used as rescue therapy in steroid-refractory UC. The aim of this study was to investigate the differences of medication use and prognosis in UC patients according to the periods of diagnosis. METHODS: From 1987 to 2012, a total of 1,422 patients with UC were retrospectively reviewed in 12 hospitals. The study population was divided into two groups according to the periods of diagnosis as follows; group A: 1987-2005, group B: 2006-2012. Analyzed variables were compared by using chi-square test and logistic regression analysis. RESULTS: Mean age of the subjects was 42.2 years, and the mean follow-up period was 4.7 years. In univariate analysis, the use of infliximab in group B was significantly higher than group A (4.5% vs. 7.6%, p=0.016), and UC-related hospitalization (45.8% vs. 40.1%, p=0.031) and UC-related surgery (6.4% vs. 3.5%, p=0.010) in group B was significantly lower than that of group A. The use of oral steroid in surgery group was significantly higher than non-surgery group in multivariate analysis (OR 1.85, 95% CI 1.03-3.30, p=0.039). CONCLUSIONS: Infliximab might play an important role for the treatment of steroid-refractory UC. Well-designed prospective trials based on the efficacy and safety of infliximab are required in the future.
